The effectiveness of mouthwash against SARS-CoV-2 infection: A review of scientific and clinical evidence

Chen, Ming Hsu; Chang, Po-Chun

doi:10.1016/j.jfma.2021.10.001

Cited by 30 publications

(27 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several proprietary mouthwash formulations contain alcohol (ethanol), and in some products, the concentration of ethanol can be as high as 26% (Huang et al, 2021 ). Moreover, in a recent review data regarding the efficacy of experimental mouthwashes against SARS‐CoV‐2 have been reported (Chen & Chang, 2021 ). Also, there is evidence that VoCs may differ in terms of biological properties (antigenicity, fitness, and transmission velocity) and therefore assessing the virucidal activity of mouthwashes with different VOCs could be helpful to obtain a more precise picture.…”

Section: Discussionmentioning

confidence: 99%

In vitro virucidal activity of mouthwashes on SARS‐CoV‐2

et al. 2022

View full text Add to dashboard Cite

Objectives The objective of the study was to evaluate the in vitro virucidal activity of commercial mouthwashes against SARS‐CoV‐2 and variants of concern. Materials and Methods Antiviral activity was assessed at different time intervals, based on common use of these products by titrating residual viral infectivity on Vero E6 cells. Results All the mouthwashes were effective to reduce the infectious titers of SARS‐CoV‐2 and its tested variants. Mouthwashes Listerine ® Cool Mint milder taste and Listerine ® Cavity Protection milder taste reduced the infectious viral titer by up to 3.9 log10 after 30 s, while mouthwash Cetilsan ® Sugar Free was able to reduce the viral titer by 2.2–2.9 log10 at all tested time intervals. Mouthwash Curasept ® ADS DNA Intensive treatment was less effective to decrease viral infectivity (0.7–2.2 log10 TCID50/ml at all tested time intervals). Interestingly, the Gamma variant appeared more resistant to treatment in vitro with the different mouthwashes. Conclusions In this study, we were able to assess the ability of different mouthwashes to in vitro decrease the infectivity of SARS‐CoV‐2 and its variants, and we observed that Gamma variant of concern was more resistant to treatment with mouthwashes.

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro virucidal activity of mouthwashes on SARS‐CoV‐2

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Previous research results evaluating ColdZyme and oral mouth rinses on common cold viruses and SARS-CoV-2 infections show all have in vitro antiviral efficacy and when applied sufficiently onto the oral mucosa reduce viral load. [10][11][12][13][20][21] This double-blind, placebocontrolled, randomized trial was conducted to evaluate the efficacy of ColdZyme in the treatment of naturally occurring common cold. The study followed a previous single-blind trial investigating the use of two different scales to assess the common cold.…”

Section: Discussionmentioning

confidence: 99%

Early intervention with ColdZyme mouth spray after self-diagnosis of common cold: a randomized, double-blind, placebo-controlled study

Lindberg¹,

Nelson²,

Ranstam

et al. 2022

Preprint

View full text Add to dashboard Cite

Background A glycerol throat spray containing cold-adapted cod trypsin creates a protective barrier and is known to deactivate common cold virus in vitro and decrease pharyngeal rhinovirus load after inoculation in humans. Early self-diagnosis and use of the medical device ColdZyme indicate a safe alternative for treatment in naturally occurring common colds. Methods This was a double-blind, randomized, parallel-group, placebo-controlled study conducted at ten German sites to evaluate the efficacy of the medical device ColdZyme, a glycerol mouth spray containing cold-adapted cod trypsin, for naturally occurring common cold, versus placebo. Adults experiencing a minimum of three common colds during the previous year, but otherwise healthy, were enrolled to begin treatment with the mouth spray or placebo six times daily at first sign of a common cold. Jacksons symptom scale and the 9-item Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) quality of life (QoL) domain and sore throat scale were recorded daily by subjects, as well as any use of allowed rescue treatment. The trial is registered at ClinicalTrials.gov, number NCT03794804. Results Between January and April 2019, 701 subjects were enrolled and randomly assigned to the ColdZyme group (n=351) or the placebo group (n=350). Of the 701 subjects, 438 (62.5%) subjects developed symptoms typical of common cold, and all 438 started study treatment (n=220 in the ColdZyme group and n=218 in the placebo group). There were no differences between the groups in primary and major secondary endpoints, however, the assessment using the WURSS-21 QoL domain and Jackson score suggests a slightly faster recovery with ColdZyme, as symptoms and complaints affecting the quality of life were shortened about 1 day. The beneficial effect of ColdZyme was particularly noticeable on the fifth day of the common cold. A positive difference between treatment groups was also seen for the subjects assessments of global efficacy of the investigational product, and a robust safety profile for ColdZyme was demonstrated throughout the study. Conclusion The safety and tolerability of ColdZyme have been confirmed in a larger study population, while establishing evidence of a slightly faster recovery from common cold symptoms. Keywords: glycerol, (cod) trypsin, common cold, quality of life, oral spray, colds viruses

show abstract

“…Este virus muestra afinidad a distintos tejidos humanos, entre estos están las células epiteliales de la córnea, intestino, riñón y dos principales que son las estructuras respiratorias y mucosa oral; en esta última se menciona al epitelio escamoso no queratinizado, las glándulas salivales (especialmente las menores), las encías, y las células epiteliales de la lengua [13][14][15][16] . Esto se debe a que la cavidad bucal sirve como punto de partida y depósito de este virus, pues es uno de ARN monocatenario con envoltura lipídica, que en su superficie presenta una estructura llamada proteína pico o espiga, la cual está implicada en el proceso de distinción del receptor y penetración a la membrana celular 15,[17][18][19] . Al interactuar el receptor primordial de la célula huésped del SARS-CoV-2, es decir, la enzima convertidora de angiotensina 2 (ACE2) con la ya citada proteína pico, es cuando se produce fácilmente el ingreso a las células; y al encontrarse estos receptores de la enzima en las distintas estructuras ya mencionadas anteriormente, indica la elevada tasa de infección que se puede encontrar en estas 13,17,19,20 .…”

Section: El Sars-cov-2 En La Cavidad Oralunclassified

“…Esto se debe a que la cavidad bucal sirve como punto de partida y depósito de este virus, pues es uno de ARN monocatenario con envoltura lipídica, que en su superficie presenta una estructura llamada proteína pico o espiga, la cual está implicada en el proceso de distinción del receptor y penetración a la membrana celular 15,[17][18][19] . Al interactuar el receptor primordial de la célula huésped del SARS-CoV-2, es decir, la enzima convertidora de angiotensina 2 (ACE2) con la ya citada proteína pico, es cuando se produce fácilmente el ingreso a las células; y al encontrarse estos receptores de la enzima en las distintas estructuras ya mencionadas anteriormente, indica la elevada tasa de infección que se puede encontrar en estas 13,17,19,20 .…”

Section: El Sars-cov-2 En La Cavidad Oralunclassified

“…Por otro lado, los efectos adversos más frecuentes comprenden pigmentación dental y variaciones en la sensación del gusto, sin embargo, se ha mencionado que tiene asociación con su uso muy extendido 8,19,24 . Según las directrices e instrucciones para el diagnóstico y tratamiento del COVID-19 publicado por la comisión Nacional de Salud del gobierno chino, da a entender que emplear la clorhexidina al 0.12% como colutorio antes de la práctica dental es deficiente para minorar la carga viral del SARS-CoV-2 25 .…”

Section: Clorhexidinaunclassified

See 1 more Smart Citation

Tendencia en el uso de colutorios como medida de bioseguridad en la atención odontológica para el contexto post COVID-19: revisión narrativa

Fernández

Tong²

2022

cietna

View full text Add to dashboard Cite

Objetivo: Conocer la tendencia en el uso de colutorios como medida de bioseguridad para la atención odontológica para el contexto post COVID-19. Método: La búsqueda bibliográfica se realizó en las bases de datos EBSCO, Scopus, PubMed, en la Biblioteca Virtual en Salud, y en el motor de búsqueda Google Scholar, algunos de los descriptores utilizados fueron "colutorios", "COVID-19", “SARS-CoV-2”, “aerosols”, entre otros. Inicialmente se seleccionaron 114 artículos de los cuales fueron descartados 19 por duplicado, 34 por no estar directamente relacionados con el objetivo del estudio y 24 por no cumplir con los criterios de inclusión, para finalmente seleccionar 38 artículos. Resultados principales: Tanto la yodopovidona como el cloruro de cetilpiridinio presentaron una efectividad viricida contra el SARS-CoV-2 del 99.99%. Conclusión principal: La utilización de la yodopovidona como el cloruro de cetilpiridinio antes de cualquier procedimiento odontológico es recomendable con la finalidad de disminuir la carga viral y microbiana eficazmente, previniendo así la transmisión de cualquier enfermedad infecciosa.

show abstract

The effectiveness of mouthwash against SARS-CoV-2 infection: A review of scientific and clinical evidence

Cited by 30 publications

References 43 publications

In vitro virucidal activity of mouthwashes on SARS‐CoV‐2

In vitro virucidal activity of mouthwashes on SARS‐CoV‐2

Early intervention with ColdZyme mouth spray after self-diagnosis of common cold: a randomized, double-blind, placebo-controlled study

Tendencia en el uso de colutorios como medida de bioseguridad en la atención odontológica para el contexto post COVID-19: revisión narrativa

Contact Info

Product

Resources

About